Upcoming Webinar: What the uniQure AMT-130 News Means for the Huntington’s Disease Community
The recent announcement from uniQure about their gene therapy for Huntington’s disease has sparked both excitement and important questions. To help unpack what this means for our community, the Huntington’s Disease Society of America (HDSA) is hosting a special two-part event featuring expert insights and live discussion.
🗓️ Thursday, October 30
🕑 2:00–4:00 PM ET
Part 1: Expert Perspectives
Hear directly from:
-
Dr. Walid Abi-Saab, Chief Medical Officer, uniQure
-
Dr. Sarah Tabrizi, Professor of Clinical Neurology and Director, UCL Huntington’s Disease Centre
They will share their perspectives on the latest AMT-130 gene therapy results and address key questions from the HD community.
Part 2: Live Q&A Discussion
Join:
-
Dr. Tam Maiuri, Associate Director, Research & Patient Engagement, HDSA
-
MaryAnn Emerick, Senior Manager, Youth & Community Services, HDSA
-
Allison Bartlett, Esq., Senior Manager, Disability Programs, HDSA
Immediately following the presentation, HDSA staff will host a live Q&A to discuss what this news means for HD families and what to expect next.
We hope you’ll join us for an honest and informative conversation about this pivotal moment in Huntington’s disease research.
👉 https://hdsa-org.zoom.us/webinar/register/3817615807788/WN_lsxS7Pq_RFeOaOwyvrNnig
